Objectives Over the past decades, rifaximin has been used to treat with small intestinal
bacterial overgrowth (SIBO), however, the true efficacy remains unknown. This systematic …

Background Small intestinal bacterial overgrowth (SIBO) is a heterogeneous syndrome,
characterised by an increased number and/or abnormal type of bacteria in the small bowel …

Background Rifaximin is a broad spectrum non‐absorbable antibiotic used for treatment of
small intestinal bacterial overgrowth. Doses of 1200 mg/day showed a decontamination rate …

Results: One drop-out was observed in rifax-imin group. Five drops-out occurred in
metronidazole group. The glucose breath test normalization rate was significantly higher in …

Background: Few controlled studies assessing choice and duration of antibiotic therapy for
small intestinal bacterial overgrowth are available. Aim: To assess efficacy, safety and …

Aliment Pharmacol Ther 2010; 32: 1000–1006 Summary Background Abnormal intestinal
clearance is involved in the pathogenesis of small intestinal bacterial overgrowth (SIBO). It is …

Background: Rifaximin is a broad-range, gastrointestinal-specific antibiotic that
demonstrates no clinically relevant bacterial resistance. Therefore, rifaximin may be useful in …

Objective: Patients with small intestine bacterial overgrowth (SIBO) have chronic intestinal
and extraintestinal symptomatology which adversely affects their quality of life. Present …

Introduction: Small intestinal bacterial overgrowth (SIBO) leads to non-specific abdominal
discomfort and nutrient malabsorption. Currently, rifaximin is widely applied in SIBO based …

Purpose Previous studies demonstrate improvement in IBS after antibiotic therapy, with the
greatest efficacy seen with the antibiotic, rifaximin. The purpose of this study was to compare …